Cleveland Biolabs Earnings Preview: Get Ahead of the Analysts

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Cleveland Biolabs (NASDAQ:CBLI) will report earnings before markets open on Tuesday, August 13th. Cleveland Biolabs, Inc. develops pharmaceuticals. The Company develops drugs to protect humans from exposure to radiation.

Here is your Cheat Sheet to Cleveland Biolabs Earnings:

Earnings Expectations: Analysts expect earnings of $-0.16 per share on revenues of $1.48 million.

Analyst Trends:

Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a loss of $0.15 to a loss $0.14. For the current year, the average estimate is a loss of $0.58, which is worse than the estimate ninety days ago.

Earnings Trends:

Here’s how Cleveland Biolabs has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 5 14 15 9 4
Diluted EPS ($) -1.13 -0.82 -1.01 -0.12 -0.49

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012 Mar. 31, 2013
Revenue ($) in millions 0.26 0.22 2.16 1.37
Diluted EPS ($) -0.14 -0.30 0.07 -0.22

Past Performance:
Cleveland Biolabs has beat analyst estimates 1 time in the past four quarters. This is not consistent enough to get bullish yet.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business